Navellier & Associates Inc Corcept Therapeutics Inc Transaction History

Navellier & Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$16.78 - $27.3 $1.79 Million - $2.92 Million	-106,862 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$12.46 - $19.98 $542,234 - $869,489	43,518 Added 68.7%	106,862 $1.86 Million
Q2 2020 Aug 12, 2020	BUY	$11.0 - $18.26 $696,784 - $1.16 Million	63,344 New	63,344 $1.07 Million
Q3 2018 Nov 14, 2018	SELL	$12.27 - $15.65 $1.4 Million - $1.78 Million	-114,041 Closed	0 $0
Q2 2018 Aug 06, 2018	BUY	$15.3 - $19.69 $29,850 - $38,415	1,951 Added 1.74%	114,041 $1.79 Million
Q1 2018 May 21, 2018	BUY	$14.59 - $25.5 $165,625 - $289,476	11,352 Added 11.27%	112,090 $1.84 Million
Q4 2017 Feb 12, 2018	BUY	$15.77 - $20.72 $980,231 - $1.29 Million	62,158 Added 161.11%	100,738 $1.82 Million
Q3 2017 Nov 14, 2017	BUY	$12.3 - $19.3 $474,534 - $744,594	38,580	38,580 $745,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.3B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.